As discussed above, belzutifan is a highly selective oral HIF-2 alpha inhibitor approved for use in VHL-mutated RCC and is now being investigated in combination with lenvatinib for patients with advanced RCC [43]. This evidence concerns the gene EPAS1 and renal cell carcinoma.